Clinical Trial Update: Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) [Phase 2]

View source ↗

Summary

Completed Phase 2 study of AP23573 (ridaforolimus) in patients with relapsed or refractory hematologic malignancies, including leukemia, myelodysplastic syndrom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Myelodysplastic Syndromes
• Myelofibrosis

Drugs mentioned

• AP23573 (deforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hematologic Malignancies, Leukemia | Phase 2 | Status: COMPLETED